Investigators conducted a meta-analysis of randomized controlled trials to assess the efficacy and safety of brolucizumab ...

In response to a report of foreign material found in a sealed vial, Alcon Laboratories has initiated a voluntary recall of ...

As 2024 comes to a close, we here at Ophthalmology Times and the greater Eye Care Network would like to thank you–the reader.

Deepinder Dhaliwal, MD, LAc, explores advancements in managing Fuchs endothelial corneal dystrophy, highlighting Descemet ...

Electrical stimulation therapy is being explored as a potential treatment to enhance neuroplasticity and improve visual ...

Alon Kahana, MD, PhD, discusses the role of interleukin-6 in thyroid eye disease and the potential of tourmaline Bio's IL-6 ...

Deepinder Dhaliwal, MD, LAc, discusses longterm outcomes of Descemet Stripping Only (DSO) for Fuchs dystrophy at NYU's ...

A Helsinki University Hospital study found diabetes, glycemic control, or insulin therapy did not significantly affect ...

The NYU Grossman School of Medicine launches a Journal Club series with Ophthalmology Times, featuring expert faculty ...

This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for. This series features experts in ophthalmology sharing their ...

CU06 showed dose-dependent improvements in visual acuity and anatomical markers in DME patients, with the 300 mg group achieving a 5.8-letter improvement. The trial confirmed CU06's safety, with no ...

4D-150, based on the R100 vector, shows superior retinal cell transduction and efficacy in preclinical models compared to AAV2. The genetic medicine 4D-150 targets neovascular retinopathies by ...